tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARGX Stock Latest News

Argenx SE Showcases Immunology Innovations at 2025 AANEM Meeting
Company AnnouncementsArgenx SE Showcases Immunology Innovations at 2025 AANEM Meeting
3d ago
6K
ARGX
Argenx price target raised to $880 from $800 at Wedbush
PremiumThe Fly
Argenx price target raised to $880 from $800 at Wedbush
4d ago
ARGX
Argenx SE Calls Extraordinary Shareholder Meeting for November 2025
PremiumCompany Announcements
Argenx SE Calls Extraordinary Shareholder Meeting for November 2025
14d ago
6K
ARGX
Argenx price target raised to $1,040 from $766 at Morgan Stanley
PremiumThe Fly
Argenx price target raised to $1,040 from $766 at Morgan Stanley
16d ago
ARGX
Vor Bio appoints Khan as Chief Medical Affairs Officer
PremiumThe Fly
Vor Bio appoints Khan as Chief Medical Affairs Officer
24d ago
VOR
ARGX
Argenx price target raised to $882 from $797 at Stifel
PremiumThe FlyArgenx price target raised to $882 from $797 at Stifel
29d ago
ARGX
Argenx Completes Phase 1 Study on ARGX-109: Key Insights for Investors
Premium
Company Announcements
Argenx Completes Phase 1 Study on ARGX-109: Key Insights for Investors
29d ago
ARGX
Argenx’s Strategic Diversification and Promising Pipeline Highlighted by Buy Rating
Premium
Ratings
Argenx’s Strategic Diversification and Promising Pipeline Highlighted by Buy Rating
1M ago
ARGX
Argenx assumed with a Buy at Truist
PremiumThe Fly
Argenx assumed with a Buy at Truist
1M ago
ARGX
Argenx downgraded to Hold from Buy at Deutsche Bank
PremiumThe Fly
Argenx downgraded to Hold from Buy at Deutsche Bank
1M ago
ARGX
Deutsche Bank downgrades Argenx to Hold after greater than 40% rally
PremiumThe Fly
Deutsche Bank downgrades Argenx to Hold after greater than 40% rally
1M ago
ARGX
Argenx’s Phase 3 Study on Efgartigimod: A Potential Game-Changer in Autoimmune Treatment
PremiumCompany Announcements
Argenx’s Phase 3 Study on Efgartigimod: A Potential Game-Changer in Autoimmune Treatment
1M ago
ARGX
Argenx Advances in Systemic Sclerosis Treatment with Efgartigimod PH20 SC Study
PremiumCompany AnnouncementsArgenx Advances in Systemic Sclerosis Treatment with Efgartigimod PH20 SC Study
1M ago
ARGX
Argenx’s Phase 3 Study on Empasiprubart: A Potential Game-Changer for MMN Treatment?
Premium
Company Announcements
Argenx’s Phase 3 Study on Empasiprubart: A Potential Game-Changer for MMN Treatment?
1M ago
ARGX
Argenx’s CIDP Study: Transitioning from IVIg to Efgartigimod PH20 SC
Premium
Company Announcements
Argenx’s CIDP Study: Transitioning from IVIg to Efgartigimod PH20 SC
1M ago
ARGX
Argenx Advances Pediatric gMG Treatment with Efgartigimod Study
PremiumCompany Announcements
Argenx Advances Pediatric gMG Treatment with Efgartigimod Study
1M ago
ARGX
Argenx’s Pediatric gMG Study: A Potential Game-Changer in Rare Disease Treatment
PremiumCompany Announcements
Argenx’s Pediatric gMG Study: A Potential Game-Changer in Rare Disease Treatment
1M ago
ARGX
Argenx’s Promising Phase 3 Study on Efgartigimod IV for ITP: A Potential Game-Changer
PremiumCompany Announcements
Argenx’s Promising Phase 3 Study on Efgartigimod IV for ITP: A Potential Game-Changer
1M ago
ARGX
Argenx’s Efgartigimod Study: A Potential Game-Changer for Ocular Myasthenia Gravis
PremiumCompany Announcements
Argenx’s Efgartigimod Study: A Potential Game-Changer for Ocular Myasthenia Gravis
1M ago
ARGX
Argenx’s Phase 3 Study on Efgartigimod PH20 SC: A Potential Game-Changer for Thyroid Eye Disease
PremiumCompany AnnouncementsArgenx’s Phase 3 Study on Efgartigimod PH20 SC: A Potential Game-Changer for Thyroid Eye Disease
1M ago
ARGX
Argenx’s Phase 2 Study on Efgartigimod PH20 SC: A Potential Game-Changer in Kidney Transplant Rejection
Premium
Company Announcements
Argenx’s Phase 2 Study on Efgartigimod PH20 SC: A Potential Game-Changer in Kidney Transplant Rejection
1M ago
ARGX
Argenx Advances Phase 3 Study for Thyroid Eye Disease Treatment
Premium
Company Announcements
Argenx Advances Phase 3 Study for Thyroid Eye Disease Treatment
1M ago
ARGX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >